0000000000719495

AUTHOR

Graham S Cooke

showing 2 related works from this author

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

2023

Abstract Background We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admiss…

MaleEpidemiologyMESH: HospitalizationMESH: Proportional Hazards ModelsMESH: Risk FactorsRisk FactorsMESH: Childcohort studyMESH: COVID-19HumansMESH: SARS-CoV-2ChildProportional Hazards ModelsMESH: HumansMESH: Middle AgedSARS-CoV-2COVID-19risk of deathGeneral MedicineMiddle AgedCOVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatmentsMESH: MaleHospitalizationIntensive Care Unitsco-morbiditiestreatmentssymptomsMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCOVID-19/therapy
researchProduct